Psoriasis Drugs Market

Psoriasis Drugs Market by Therapeutic Classes (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin-D Analogues, and Others), Treatments (Topicals [Steroids, OTC Drugs, and Non-Steroids], Systemic, and Biologics), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-975
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 198
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global Psoriasis drugs market size was valued at USD 14.9 billion in 2020 and is anticipated to expand at a significant CAGR of 9.3% during the forecast period, 2021-2028. The growth of the market is attributed to the rising awareness in regard to the treatment of Psoriasis along with the increasing demand for the improved healthcare infrastructure of various developing economies.
 

Psoriasis Drugs Market Key Takeaways


Psoriasis is a pre-defined genetic condition which is not present at the time of birth. It is a condition which might be triggered from the cause of genetic and environmental factors. Skin cells tends to build up forming itchy, dry, and scaly patches. This disease ca be affected when there are multiple problems in the host’s immune system which can be both medical in terms of having frequent infections & common cold and psychological in terms of poor stress & anger management. The main treatment aim from the Psoriasis drugs perspective is to remove the scales from the skin of the host and to halt the rapid growth of skin cells.

According to the International Federation of Psoriasis Association in 2019, more than 5% of the entire world population suffer from at least one form of psoriasis. In North America, the Centre for Disease Control and Prevention or the CDC reported more than 7.5 million people being affected by psoriasis which is approximately 2% of the globe population. Moreover, there are more than 100,000 new cases being reported and registered every year. The COVID-19 pandemic has hindered the growth of global Psoriasis drugs market initially. However, scientists & researchers, upon further research, reported & identified that the coronavirus has numerous viral genes that can accelerate the present weakness of the hosts. This leads to the rapid arrangement of clinics, healthcare laboratories, and hospitals to expand novel innovations in Psoriasis drugs. This has led to its market growth in the later stages of the pandemic.

Market Trends, Drivers, Restraints, and Opportunities

  • Increase in spending and investing by key companies towards the development of new and advanced Psoriasis drugs along with the latest research and development studies are primary reasons to boost the market growth during the forecast period.
  • Rapid growth of the biopharmaceutical companies and existing wide demand for Psoriasis drugs worldwide are major factors that help boost the market.
  • High prices for the development of Psoriasis drugs and high cost of services from the company’s perspective are anticipated to hinder the global market growth.
  • Psoriasis drugs are advised to be used under medical supervision and failure to comply this can lead to various side-effects ranging from dry lips, cracked skin, hair loss, nosebleed to depression and vision impairments. This can hamper the Psoriasis drugs market growth.
  • R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have found novel methods for the treatment of psoriasis apart from drugs such as the IL-inhibitor therapy which used along with the Remicade & Humira shows the most effective treatment for Psoriasis till date.

Scope of the Report

The report on the global Psoriasis drugs market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Psoriasis Drugs Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Therapeutic Classes (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin-D Analogues, and Others) and Treatments (Topicals [Steroids, OTC Drugs, and Non-Steroids], Systemic, and Biologics)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast

Key Players Covered in the Report

AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celegene Corporation; UCB; Merck; Boehringer Ingelheim; and LEO Pharma

 

Global Psoriasis Drugs Market Segment Insights

Tumor necrosis factor inhibitors segment is projected to represent a large market share
Based on therapeutic classes, the global Psoriasis drugs market is divided into tumor necrosis factor inhibitors, interleukin inhibitors, vitamin-D analogues, and others. The tumor necrosis factor inhibitors segment constituted a major market share in 2019. The major reason for this segment growth is the use of the most effective drugs used for the treatment of Psoriasis in tumor necrosis factor inhibitors namely Humira (adalimumab), Remicade (infliximab), Cimzia (certolizumab pegol), and Enbrel (etanercept).
Meanwhile the interleukin inhibitors segment is anticipated to expand at a significant CAGR during the forecast period, owing to the improved efficacy and safety profiles along with the increasing adaption amongst end-users. Latest drugs with more effectiveness such as Cosentyx (secukinumab), Stelara (ustekinumab), Tremfya (guselkumab), Ilumya (tildrakizumab), Siliq (brodalumab), and Taltz (ixekizumab) have all been approved under interleukin inhibitors for the treatment of psoriasis.
 

Psoriasis Drugs Market By Therapautic Classes


Biologics segment is anticipated to register a large market share
On the basis of treatments, the global Psoriasis drugs market is segmented into topicals, systemic, and biologics. The topicals segment is further divided into steroids, OTC drugs, and non-steroids. The biologics segment constituted a major market share in 2019 and is anticipated to expand at a significant CAGR during the forecast period. The major reason for this segment growth is the methodology of the biologics and how they perform. Biologics have a different approach in terms of specifically targeting the weak immune system areas of the host and formulating drugs to strengthen this core. This method can provide specific drugs to certain patients resulting in limited side-effects compared to other methods.

North America is anticipated to dominate the market
On the basis of regions, the global Psoriasis drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to dominate the global market with a 37.9% market share in the coming years owing to the growing research & development expenditure along with the rising in adoption of the latest technology in the region. The demand of Psoriasis drugs is increasing rapidly in this region due to the presence of the major market players in the market. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR of 12.9% during the forecast period, 2021-2028 as they have prioritized the cost-efficiency perspective of Psoriasis drugs combined with their growing population.

Psoriasis Drugs Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Psoriasis Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Psoriasis Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Psoriasis Drugs Market - Supply Chain
  4.5. Global Psoriasis Drugs Market Forecast
     4.5.1. Psoriasis Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Psoriasis Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Psoriasis Drugs Market Absolute $ Opportunity
5. Global Psoriasis Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Psoriasis Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Psoriasis Drugs Demand Share Forecast, 2019-2026
6. North America Psoriasis Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Psoriasis Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Psoriasis Drugs Demand Share Forecast, 2019-2026
7. Latin America Psoriasis Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Psoriasis Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Psoriasis Drugs Demand Share Forecast, 2019-2026
8. Europe Psoriasis Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Psoriasis Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Psoriasis Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Psoriasis Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Psoriasis Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Psoriasis Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Psoriasis Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Psoriasis Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Psoriasis Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Psoriasis Drugs Market: Market Share Analysis
  11.2. Psoriasis Drugs Distributors and Customers
  11.3. Psoriasis Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. AbbVie Inc.
     11.4.2. Amgen Inc.
     11.4.3. Johnson & Johnson
     11.4.4. Novartis AG
     11.4.5. Eli Lilly & Company

Segments Covered in the Report
The global Psoriasis drugs market size has been segmented in terms of

Therapeutic Classes

  • Tumor Necrosis Factor Inhibitors
    • Interleukin Inhibitors
    • Vitamin-D Analogues
    • Others

Treatments

  • Topicals
  • Steroids
  • OTC Drugs
  • Non-Steroids
  • Systemic
  • Biologics

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly & Company
  • AstraZeneca
  • Celegene Corporation
  • UCB
  • Merck
  • Boehringer Ingelheim
  • LEO Pharma

Major players competing in the global Psoriasis drugs market are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celegene Corporation; UCB; Merck; Boehringer Ingelheim; and LEO Pharma. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Eli Lilly & Company, in September 2019, announced the business expansion towards the emerging markets & developing nations such as China, India, and South Korea and have begun to adopt various strategies which includes both alliances and acquisitions that lead to the development of newer products.
 

Psoriasis Drugs Market By key Players

Buy Report